Novartis Investigative Site

St'Petersburg 197341

0 studies enrolling now · 8 studies all time

What they study most

Acute Leukaemia, Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic, Lymphoma, Follicular, Thrombocytopaenia

Studies at this site

• Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia — Completed
• Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy — Stopped early
• A Safety and Efficacy Study of Eltrombopag in Subjects With AML — Completed
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — Stopped early
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia — Stopped early
• A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) — Stopped early
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia — Completed
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) — Completed